Latest News – EmphyCorp Proprietary Non-Steroidal N115

Up until the recent acclaim of EmphyCorp’s proprietary technology, N115, the primary treatment for Pulmonary Fibrosis, Cystic Fibrosis, Allergic Rhinitis, Unmet Needs and Chronic Obstructive Pulmonary Disease (COPD) Patients was the use of Corticosteroids. Corticosteroids are typically involved in a very wide range of physiological processes such as the body’s stress response, immune response and regulation of inflammation, carbohydrate metabolism, protein catabolism, blood electrolyte levels and overall behavior.

However, Corticosteroids are certainly not a reliable form of treatment, as well documented studies have shown that any prolonged use of Corticosteroids may have serious side effects including the potential for fatality. Other marketed drugs that directly treat pulmonary diseases are also reported to produce substantial damage to the body, mainly in areas such as the central nervous system, cardiovascular system, respiratory system and an abrupt disruption within the gastrointestinal system.

Until this day, EmphyCorp N115 remains one of the most effective and one of the safest on the entire market. With this form of unique technology, patients are no longer prone to experiencing the common complications to that of Corticosteroids.

Each treatment involving synthetic pharmaceutical drugs that feature Corticosteroid-like effects should come with a flamboyant warning label. These Corticosteroid-like effects are used to “treat” a variety of conditions, mainly ranging from brain tumors to that of an individual’s case of skin disease.

Both clinical and experimental evidence has indicated that Corticosteroids are capable of causing permanent eye damage by inducing a form of central serous retinopathy, also recognized as central serous chorioretinopathy that causes an optical disease which causes visual impairment in one eye.

EmphyCorp globally patented Non-Steroidal Technology, is a naturally occurring antioxidant of the human body, has been shown to significantly reduce inflammatory agents throughout the human body, including the lungs  and nasal cavity and produced statistically  and clinically significant increases in  lung function measurements, including FEV-1, FVC, PEF, SaO2, and FEV-1/FVC ratios, Nitric oxide and reduced nasal and lung  inflammation and congestion.

Eight Phase I/II and partial Phase III human studies and Eight human nasal studies were submitted to the FDA in Patients with, COPD, Pulmonary Fibrosis, and Cystic Fibrosis (CF) for our NDA submission.

Over one and a half million nasal spray units have been used to treat patients in over 100 hospitals, including an estimated 150,000 patients with COPD, and Patients with Unmet Needs, which includes Pregnant Women, small children, diabetics, and hypertensive who suffer from nasal congestion, nasal drip, Inflammation, but cannot take any nasal sprays with steroids. No adverse events were reported.